Compile Data Set for Download or QSAR
Report error Found 29 Enz. Inhib. hit(s) with all data for entry = 7137
TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790989BDBM790989(US20260034252, Compound RTX-1352S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790987BDBM790987(US20260034252, Compound RTX-1318S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790986BDBM790986(US20260034252, Compound RTX-1350S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790998BDBM790998(US20260034252, Compound RTX-1359R)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790995BDBM790995(US20260034252, Compound RTX-1357R)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790996BDBM790996(US20260034252, Compound RTX-1324S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790992BDBM790992(US20260034252, Compound RTX-1354S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791001BDBM791001(US20260034252, Compound RTX-1361R)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791002BDBM791002(US20260034252, Compound RTX-1363S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791000BDBM791000(US20260034252, Compound RTX-1360S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790981BDBM790981(US20260034252, Compound RTX-1316S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790982BDBM790982(US20260034252, Compound RTX-1341S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790977BDBM790977(US20260034252, Compound RTX-1312S)
Affinity DataIC50: 0.100nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790990BDBM790990(US20260034252, Compound RTX-1320R)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791003BDBM791003(US20260034252, Compound RTX-1399R)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790988BDBM790988(US20260034252, Compound RTX-1319R)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790984BDBM790984(US20260034252, Compound RTX-1317S)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790980BDBM790980(US20260034252, Compound RTX-1340S)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790993BDBM790993(US20260034252, Compound RTX-1355R)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790978BDBM790978(US20260034252, Compound RTX-1339S)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790994BDBM790994(US20260034252, Compound RTX-1356R)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790991BDBM790991(US20260034252, Compound RTX-1353S)
Affinity DataIC50: 0.300nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790985BDBM790985(US20260034252, Compound RTX-1318R)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790983BDBM790983(US20260034252, Compound RTX-1317R)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790999BDBM790999(US20260034252, Compound RTX-1326S)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790997BDBM790997(US20260034252, Compound RTX-1325S)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790979BDBM790979(US20260034252, Compound RTX-1316R)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790975BDBM790975(US20260034252, Compound RTX-1309R)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent

TargetProlyl endopeptidase FAP(Human)
Ratio Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 790976BDBM790976(US20260034252, Compound RTX-1312R)
Affinity DataIC50: 2.75nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/17/2026
Entry Details US Patent